Molecular Hydrogen Ocular Compositions for Low-Toxicity Tissue Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular conditions often result in adverse effects such as toxicity, allergic reactions, and incomplete treatment delivery, and many medications are ineffective or difficult to use, highlighting a need for safer and more effective therapies.
Innovation Solution
Formulations and methods utilizing molecular hydrogen (H2) and oxyhydrogen (HHO) for treating ocular conditions, including gels, ointments, and delivery systems that provide therapeutic compositions to the eye, reducing inflammation and promoting healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (steroids, eye-drops) are used to treat ocular conditions, then inflammation reduction is achieved, but adverse effects (toxicity, allergic reactions, cataracts, infections, elevated intraocular pressure) occur
Solution Approach 1:
The patent changes the chemical composition parameter from conventional steroids and eye-drops to molecular hydrogen (H2) and oxyhydrogen compositions. This parameter change provides anti-inflammatory effects while eliminating the toxic side effects associated with traditional treatments, as H2 is a safe, biocompatible gas that does not cause the adverse reactions typical of steroid-based therapies.
Solution Approach 2:
The patent extracts and eliminates the harmful components from conventional ocular treatments. By using pure molecular hydrogen gas or oxyhydrogen compositions without the toxic additives, preservatives, and complex formulations found in traditional eye-drops and steroid medications, the invention removes the source of adverse effects while retaining therapeutic benefits.
2Ease of operation
If eye-drops and conventional delivery methods are used, then treatment is administered, but incomplete contact with the eye and difficult patient use occur
Solution Approach 1:
The patent utilizes gaseous molecular hydrogen or oxyhydrogen compositions that can be delivered via inhalation or direct ocular application. The gas phase allows for complete contact with the ocular surface without the mechanical challenges of liquid eye-drops, improving both patient ease of use and treatment completeness through natural gas diffusion and dissolution into ocular tissues.
Solution Approach 2:
The patent employs composite delivery systems that may combine molecular hydrogen gas with carrier vehicles or delivery devices. This composite approach allows flexible administration methods that are both easy for patients to use and ensure complete therapeutic contact with the eye, overcoming the limitations of conventional liquid drop formulations.
3Adaptability or versatility
If many conventional medications are used to treat ocular conditions, then treatment coverage is provided, but clinical effectiveness is reduced in many patients
Solution Approach 1:
The patent changes the therapeutic agent parameter from conventional medications with variable patient responses to molecular hydrogen, a universal anti-inflammatory and antioxidant agent. H2's ability to modulate signal transduction across multiple pathways and its role as a selective antioxidant provide consistent clinical effectiveness across diverse patient populations, addressing the variability problem with traditional medications.
Solution Approach 2:
Molecular hydrogen serves multiple therapeutic functions simultaneously: it acts as an antioxidant, anti-inflammatory agent, and cytoprotective substance. This multi-functionality provides broad treatment coverage for various ocular conditions while maintaining consistent effectiveness, eliminating the need for multiple different medications with varying patient responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of molecular hydrogen and oxyhydrogen compositions effectively reduces inflammation, minimizes scarring, and promotes re-epithelialization, providing a safer and more effective treatment for ocular conditions.
Implementation Method 1
Molecular hydrogen (H2) is a flammable, colorless, odorless gas that can act as a reducing agent under certain circumstances
Implementation Method 2
it is a strong antioxidant reducing the level of toxic hydroxyl radicals
Data Source
AI summary
Provided herein are compositions and methods that include hydrogen gas or a mixture of hydrogen gas and oxygen gas or a solution of hydrogen and oxygen for ocular therapies and tissue healing. The compositions can be incorporated into a container with a quick-release seal allowing for efficient topical administration of the medicaments of the composition to tissues desired for treatment, such as the human eye.